This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma (MAGNETISMM17)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05462639
Expanded Access Status : Available
First Posted : July 18, 2022
Last Update Posted : September 11, 2023
Information provided by (Responsible Party):

Tracking Information
First Submitted Date June 20, 2022
First Posted Date July 18, 2022
Last Update Posted Date September 11, 2023
Descriptive Information
Brief Title Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
Brief Summary

Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.

This expanded access protocol will provide access to elranatamab until it becomes commercially available to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option.

Detailed Description

Study C1071017 is a single-arm, open-label study in patient with relapsed /refractory multiple myeloma.

Each patient will receive study intervention until disease progression, unacceptable toxicity, withdrawal of consent, study termination or until elranatamab becomes commercially available.

Study Type Expanded Access
Expanded Access Type Treatment IND/Protocol
Intervention Drug: Elranatamab (PF-06863135)
BCMA-CD3 bispecific antibody
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Contact: Pfizer Call Center 1-800-718-1021
Listed Location Countries Canada,   United States
Removed Location Countries  
Administrative Information
NCT Number NCT05462639
Current Responsible Party Pfizer
Original Responsible Party Same as current
Current Study Sponsor Pfizer
Original Study Sponsor Same as current
Collaborators Not Provided
Study Director: Pfizer Call Center Pfizer
PRS Account Pfizer
Verification Date September 2023